Drospirenone/E2 reduces BP in postmenopausal women with hypertension
Hormonal therapy with drospirenone plus estradiol (E?) lowers blood pressure and spares potassium in postmenopausal women on hydrochlorothiazide (HCTZ). So say results of a small randomized, placebo-controlled trial presented at the 17th annual NAMS meeting.
Hormonal therapy with drospirenone plus estradiol (E2) lowers blood pressure and spares potassium in postmenopausal women on hydrochlorothiazide (HCTZ). So say results of a small randomized, placebo-controlled trial presented at the 17th annual NAMS meeting.
Thirty-six women taking 25 mg/d of HCTZ for stage 1 hypertension were included in the crossover study, conducted by investigators from the University of Miami and Berlex Laboratories. The participants were randomized to 3 mg drospirenone/E2 or placebo for 4 weeks and then crossed over for another 4 weeks.
Drospirenone/E2 reduced systolic and diastolic blood pressure by 7.2 mm Hg and 4.5 mm Hg, respectively, and potassium was 0.2 mEq/L higher than with placebo. The only significant adverse effects of the hormonal therapy were vaginal bleeding and breast tenderness.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
